One RCT in patients with ACLF demonstrated significant improvement in liver disease severity measures, reduced development of multi-organ failure and other complications (including sepsis) and a >2-fold 60-day survival rate after 30 days G-CSF therapy (n = 23–24 per group). Here, CSF3 is linked to Sepsis.